ZYLOXTB2190.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, ZYLOXTB (2190.HK) trades at a P/E of 19.80x, P/B of 2.02x, P/S of 5.01x, and a dividend yield of 1.26%.
Longitudinal percentile comparison: P/E sits at the 1st percentile over the trailing 10Y window (vs. 1st percentile over 3Y); P/B sits at the 70th percentile over the trailing 10Y window (vs. 66th percentile over 3Y); P/S sits at the 6th percentile over the trailing 10Y window (vs. 12th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 61st percentile within its industry and the 73rd percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 3.84%, ranking at the 96th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 69.5 points apart — worth checking the full percentile matrix on this page for the complete picture. The P/E percentile sits lower within its industry than across the market as a whole — relatively cheaper next to direct peers. Of the 3.84% total shareholder yield, 1.26% is paid out as dividends and roughly 2.58% is implied to come from buybacks — both channels are meaningfully in play. ZYLOXTB operates in the Other Pharmaceuticals and Medical Services sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 2190 · SEHK: 2190 · 2190
Want the full picture on whether ZYLOXTB (2190.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 19.80 | ||||||
| P/B (MRQ) | 2.02 | ||||||
| P/S (TTM) | 5.01 | ||||||
| Dividend Yield | 1.26% | ||||||
| Buyback + Div Yield | 3.84% |